Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Der Kommentar von Lorenz wurde ignoriert. Um die Kommentare von Lorenz wieder zu sehen, klicken Sie folgenden Link:
Gibt immer etwas viel zu lesen hier, s. Links:
Der Kommentar von Emil wurde ignoriert. Um die Kommentare von Emil wieder zu sehen, klicken Sie folgenden Link:
Da kann man sich auch wieder betätigen, immer etwas GENE haben ist ganz gut:
06.03.2018 | 15:17
MUNICH, March 6, 2018 /PRNewswire/ --
Blockchain Genomics Pioneer Joins Forces with Nasdaq-Listed Molecular Diagnostics Company To Accelerate Cancer Detection Through 'Critical Mass' of Genomics Data
Shivom, the blockchain-powered global 'Unique ID' genomic database platform, has today announced a major partnership with leading molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide.
GTG, whose lead product is BREVAGenplus - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine. However, collecting data to develop the BREVAGenplus tests has to date taken over seven years and the company's partnership with Shivom will massively reduce such timelines.
"By bringing together the millions of individuals' genomic profiles that Shivom enables, with GTG's market leading tests, we will create critical mass that accelerates transformative disease prevention and personalized healthcare," said Dr. Axel Schumacher, co-founder & CEO of Shivom.
"This sort of big data analysis and healthcare servicing is only possible through blockchain. The low-cost management of data that it enables, allows us to revolutionize how genomics is presented to the world," added Gourish Singla, Co-Founder & COO of Shivom.
Shivom have created a secure global genomic ecosystem that aims to become the largest healthcare data-hub on the planet. Crucially it puts ownership of genome data back into the hands of individuals. Via its 'first of a kind' Global Genome ID, Shivom aims to revolutionize preventative healthcare, as well as how cures to 7,000 rare genetic diseases are discovered.
"We believe blockchain technology will open up markets to make it much more efficient to catch many more users and practitioners. Not only that, by using the Shivom platform to its full potential, we will also be able to access the benefits of research in collaboration with other personalized healthcare organisations," commented Dr Paul Kasian, Chairman & Interim CEO of GTG.
"Blockchain's role in this project, especially around the encryption and management of data, is particularly exciting for us. At present, we only use genomic data on a one-off basis. However, now we'll be able to use the data over and over again. This will be extremely valuable for GTG as we create genomics tests for a wide range of cancers," added Dr Kasian.
GTG's BREVAGenPlus provides a method of assessing the risk of non-hereditary breast cancer in women (a cancer that 1 in every 11 women develops in their lifetime). The volume of unique and ethnically diverse global genomic data that will be available via Shivom's platform will hugely accelerate this process for new tests.
Shivom is powering the next era of genomics through blockchain technology - protecting identity, personalizing healthcare and transforming lives. A precision medicine ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics, and associated apps and services to drive personalized medicine. For further information, please visit: https://shivom.io/
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company offering cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead product, BREVAGenplus is a clinically validated risk assessment test for non-hereditary breast cancer. For more information, please visit http://www.brevagenplus.com and http://www.phenogensciences.com.
© 2018 PR Newswire
Zur Info / News:
Genetic Technologies announces collaborative research with the University of Melbourne to broaden the applicability of the BREVAGenplus breast cancer risk assessment test
Mar. 16, 2018 7:08 AM ET|By: Mamta Mayani, SA News Editor
Genetic Technologies (NASDAQ:GENE) executes a research and services agreement with The University of Melbourne for the further development and enhancement of the BREVAGenplus breast cancer risk assessment test.
The research is designed to broaden the applicability of the BREVAGenplus breast cancer risk assessment test enabling its use by women with an extended family history of disease and will also increase the range of risk factors analyzed.
The terms of the agreement are not disclosed.
Und von GENE:
1 May 2018
NHMRC Partnership Grant awarded to University of Melbourne Collaborators Aims to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility
Melbourne, Australia, 1 May 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.
Genetic Technologies’ Scientific Director, Dr Richard Allman is a co-investigator on this award which aims to substantially improve breast cancer risk prediction, but importantly, also aims to improve patient accessibility to such a test. There is growing acceptance of SNP-based risk assessment both within the medical and scientific communities. One of the key commercial barriers is clinical validity and this research program will expand the current knowledge base to inform strategies for wider-scale community adoption. As the sole commercial partner, a major benefit is that the Company, under this collaboration will have the right of first refusal to commercialise any new scientific discoveries.
Professor John Hopper, Director (Research) of the Centre for Epidemiology and Biostatistics stated that; “This prestigious grant award provides us with significant impetus to translate our scientific work into the clinical arena. We have identified potential improvements to current risk assessment paradigms, which if proven have the potential to improve breast cancer screening and prevention programs substantially.”
Genetic Technologies’ Scientific Director, Dr Richard Allman commented; “I am extremely pleased to be associated with Professor Hopper’s team as a co-investigator on this award. The project team has the necessary expertise to complete the proof-of-concept research, implement the new technology in the commercial arena and generate the ancillary research needed to confirm the expected clinical utility of the new predictive models”.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul Kasian Jason Wong (USA))
Director & Interim CEO Blueprint Life Science Group
Genetic Technologies Limited +1 (415) 375 3340, Ext. 4
+ 61 3 8412 7000 Genetic Technologies Limited • Website: www.gtglabs.com • Email: email@example.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040
About The University of Melbourne
Founded in 1853, The University of Melbourne is an internationally recognised, research-intensive university with a strong tradition of excellence in teaching, research and community engagement spanning more than 160 years.
Its outstanding performance in international rankings puts The University of Melbourne at the forefront of higher education globally. It is ranked number 1 in Australia by the Times Higher Education World University Rankings and 32nd worldwide. Melbourne’s position as Australia’s top University has also been reaffirmed in the 2017 Shanghai Jiao Tong rankings, in which it has moved up to 39th in the World.
The University is uniquely located on the fringe of the city of Melbourne’s central business district. It serves as a hub for the Parkville research precinct – one of the world’s leading centres of medical and biotechnological research.
About 50,000 of the best and brightest students from around the globe come to study at the University of Melbourne.
About Genetic Technologies Limited
Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
Quartalsbericht Ende März 2018:
Hier gab es diese Woche auch mal wieder News:
Genetic Technologies closes agreement with Project Shivom
Jun. 7, 2018 7:02 AM ET|By: Mamta Mayani, SA News Editor
Genetic Technologies (NASDAQ:GENE) has entered into a binding agreement with Omix Ventures Private Limited (“Project Shivom”), formalising the business relationship originally documented in the non-binding term sheet announced three months ago.
GTG will receive US$200K from Project Shivom 180 days from the signature of the original terms sheet, as an initial payment to commence the R&D and product development activities. The balance of any cost will be jointly funded by the parties.
Project Shivom recently completed their initial fundraising initiative, bringing in US$35M which will facilitate the commencement of its goal to establish a Precision Medicine “ecosystem” – a decentralised blockchain where people can get their genome sequenced and stored.
Previously: Genetic Tech to team up with Project Shivom to create large genetic database (March 6)
1,065 people get GENE breaking news and analysis by email alert
Get email alerts on GENE
Genetic Technologies announces Heads of Agreement with Swisstec
Jun. 19, 2018 8:45 AM ET|By: Mamta Mayani, SA News Editor
Genetic Technologies (NASDAQ:GENE) has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will develop a service platform using blockchain technology.
Whilst the terms of the agreement remain confidential, the key terms underlying the establishment of the JV Company are as follows;
GTG and Swisstec will each hold 50% of the fully paid ordinary shares on issue on incorporation, the board of directors will comprise of 2 directors nominated by each party and GTG will receive an equity stake in Swisstec of up to 20%.
PJV establishment is intended to be executed no later than mid July.
Click to subscribe to real-time analytics on GENE
Now read: What Is The Next Step For MannKind's Trep-T »
Anbei mal wieder was von GENE,für die, die da noch traden:
16 July 2018
Genetic Technologies Limited announces the expansion of its range of genetic risk assessment tests plus the October launch of its new breast cancer and colorectal cancer tests.
Melbourne, Australia, 16 July 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that both its new breast cancer and colorectal cancer risk assessment tests are on track for release in October 2018. In addition the company has already commenced development of other cancer and disease targets for its predictive technologies. The company expects to have the following tests available over the next 12 months:
· Prostate Cancer
· Type 2 Diabetes
· Cardiovascular Disease
For perspective, there are 17.7 million deaths per annum due to cardiovascular disease, 8.2 million deaths per annum due to cancer and 1.6 million deaths per annum due to diabetes. (Source: World health Organisation).
Genetic Technologies Chairman and CEO, Dr Paul Kasian commented: “This is a very exciting time for GTG. We are now offering an opportunity for doctors to improve their ability to assess a patient’s breast cancer risk. Our new test, when combined with BRCA testing, will account for almost 100% of breast cancers. Currently BRCA testing alone only accounts for 5 to 10% of breast cancers. Added to this our expanded range of tests will allow doctors to assess a patient’s risk to some of the most common causes of morbidity and mortality. ”
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul Kasian
Jason Wong (USA))
Director & Interim CEO
Blueprint Life Science Group
Genetic Technologies Limited
+1 (415) 375 3340, Ext. 4
+ 61 3 8412 7000
Genetic Technologies Limited · Website: www.gtglabs.com · Email: firstname.lastname@example.org ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040
Der Kommentar von Simona wurde ignoriert. Um die Kommentare von Simona wieder zu sehen, klicken Sie folgenden Link:
GENE-Info für Interessierte und Investierte:
30 July 2018
Appointment of Swisstec as Non-Exclusive Asian Distributor
Melbourne, Australia, 30 July 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”). This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia. As a provider of radiology solutions, Swisstec has established relationships with hospitals and healthcare organisations in the region and can assist GTG in the development of distribution channels for a suite of genetic screening tests.
The Agreement is supplemental to the Heads of Agreement between the parties announced to the market on 19 June 2018 and represents a significant step in GTG’s plans to enter new markets and expand global adoption of its predictive risk assessment tests.
In exchange for the rights to introduce the GTG screening tests into hospitals in Asia, GTG will acquire a 5% equity stake in Swisstec with the potential to secure an additional 5% subject to achievement of agreed milestones. GTG will support this new initiative by providing Swisstec with $250k to facilitate their expansion into China.
Dr Paul Kasian, Genetic Technologies’ Chairman commented: “This agreement expands on our collaboration with Swisstec and gives us the means to investigate ways we can improve patient outcomes through genetic screening for disease in Asia.”
Costar Pouzoulis, CEO of Swisstec further commented: “Because we are already dealing with hospital networks through our radiology services, we are in a unique position to introduce GTG’s genetic screening tests to hospitals in Asia. We feel this is an important step towards helping people in the region manage their health and prevent disease.”
Dr Paul Kasian Jason Wong (USA)
Chairman and Interim CEO Blueprint Life Science Group
Genetic Technologies Limited +1 (415
Da geht was:
8 August 2018
Genetic Technologies Secures A$20 Million
Equity Placement Facility
Melbourne, Australia, 8 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position.
Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months. Proceeds from the Facility will be used for general working capital purposes and to fund the Company’s activities as it seeks to:
commercialise existing R&D capabilities, IP and introduce an enhanced BREVAGenplus breast cancer risk assessment test and a colon cancer risk assessment test;
progress development of a suite of genetic screening tests targeting both cancer and non-oncological diseases utilising the latest technology and platforms, and
explore and capitalise on Blockchain opportunities in the medical and biotech industries.
Drawdowns under the Facility occur based on terms set by the Company, including the timing, drawdown amount and minimum issue price.
Commenting on the Facility, Genetic Technologies’ Chairman, Dr Paul Kasian said: “We are delighted to have signed the A$20 million Facility with Kentgrove Capital. Subject to the terms outlined below, the Facility will assist the Company with its ongoing funding requirements as it seeks to develop a range of risk prediction tests that are designed to assist in the early detection of cancer and help physicians improve patient outcomes. Blockchain technology presents a unique opportunity for the Company to further contribute to the advancement of cancer research.”
Key terms of the Equity Placement Facility
1. Facility amount of up to A$20,000,000.
2. Maturity date 7 April 2020 (20 months from date of execution).
3. Genetic Technologies may undertake multiple placements under the Facility, up to the maturity date.
4. For each new placement, Genetic Technologies determines the time period of the placement, the maximum amount of the placement (up to A$1 million, or an amount equal to the total
number of collateral shares (defined below) on issue multiplied by the minimum issue price, or a higher amount by mutual agreement) and the minimum issue price.
5. For each new placement, shares are issued at a 4.5% discount to a volume weighted average price (VWAP) of the shares traded by Kentgrove Capital over the period of the placement, but cannot be less than the minimum issue price determined by Genetic Technologies.
6. The issuance of shares under the Facility is required to be in compliance with ASX Listing Rule 7.1. Initial drawdowns under the Facility may be made within the Company’s current placement capacity. Shareholder approval in relation to the balance of the Facility may be sought at a General Meeting as required.
7. The provision of funding by Kentgrove Capital under the Facility is subject to a number of conditions, including that the market price be no lower than the minimum issue price set by Genetic Technologies, and other conditions customarily included in facilities of this nature.
8. An upfront establishment fee satisfied by the issue to Kentgrove Capital of 8,833,100 shares and 12,500,000 3-year options with an exercise price per option of $0.0153.
9. 100,000,000 collateral shares will be issued to Kentgrove Capital on execution as security for the Facility. Upon termination or expiration of the Facility, any outstanding collateral shares will be, at the Company’s election, sold by Kentgrove Capital and the proceeds returned to the Company (less a discount of 4.5%) or bought back by the Company for a nominal figure.
10. Either the Company or Kentgrove Capital may terminate the Facility, by giving 14 days' notice, other than during the first 90 days of the Facility during which it may only be terminated with cause, in accordance with the termination provisions as defined within the Facility.
11. Kentgrove Capital has given an undertaking to the Company that it will not, during the 3 months following the execution of the Facility, exercise the establishment options or dispose of the establishment fee shares.
Further details regarding the Facility will be provided in the prospectus required to be lodged by the Company in conjunction with the Facility
8 August 2018
Lodgement of Prospectus
Melbourne, Australia, 8 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE,
“Company”, “GTG”) is pleased to advise that it has lodged the attached Prospectus with ASIC.
The Company recently announced that it has entered into a $20million equity placement facility with
Kentgrove Capital Pty Ltd ACN 150 638 627 (Kentgrove) to strengthen the Company’s funding position.
Following the execution of the Kentgrove facility and under the Prospectus, the Company will offer and issue to Kentgrove:
8,833,100 Shares in lieu of payment of the Establishment Fee (Establishment Shares);
12,500,000 Options exercisable at $0.0153 each and expiring 3 years after issue
(Establishment Options); and
100,000,000 Shares as security for the Company's obligations under the Kentgrove Facility
Under the Prospectus, the Company will also have the ability to offer and issue up to 441,655,004
Shares (Placement Shares) either to Kentgrove under the Kentgrove Facility, or to other investors as
determined by the board, to raise up to $5,000,000.
An Appendix 3B is also attached with respect to the offers being made under the Prospectus.
Chairman and Interim CEO
7 August 2018
Melbourne, Australia, 7 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides the following updates to recent announcements with regards to collaborations with Swisstec Health Analytics Ltd. (“Swisstec”).
1. Progress on Swisstec Heads of Agreement
The Sunset period to finalise a Proposed Joint Venture (refer 19 June 2018 announcement) to establish a new company to enable Swisstec and the Company to collaborate to develop a medical and health service platform using blockchain technology has expired. However, neither party has terminated the Heads of Agreement and the Heads of Agreement remains on foot unless it is subsequently terminated by either party on notice. The Company continues to progress discussions with Swisstec regarding the establishment of this new joint venture company and the parties are continuing to work together to identify potential collaborative opportunities.
2. Arrangements with Swisstec regarding Asian distribution
The Company wishes to clarify that the agreement recently entered with Swisstec (refer 30 July 2018 announcement) sets out the principal commercial terms on which the Company intends to appoint Swisstec as a non-exclusive distributor for hospitals in Asia, and imposes binding obligations on the parties to negotiate in good faith in order to enter a formal distribution agreement. It is expected that formalisation and entry of a distribution agreement will occur once Swisstec has presented the Company with formal proposals for specific hospitals in the Asian region. Further updates will be provided in this regard as required.
Sorry für die Verspätung, einige von uns sind halt noch in Ferien oder machen erst jetzt welche:
Gute News heute:
17 September 2018
GTG Invited to Establish a Market Presence in Hainan, China
Melbourne, Australia, 17 September 2018: Hainan Resort Software Community(“HRSC”) has on behalf of Hainan Ecological Smart City Group (“HESCG”) formally extended an invitation to Genetic Technologies Limited (“GTG”) to establish its planned market entry into China via the Hainan Free Trade Zone initiative. As previously reported to the market on 21 August 2018, participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market with an estimated value in excess of US$800B. Companies approved to operate in China as part of the Hainan Free Trade Zone Initiative can take advantage of significant tax benefits, subsidies and investment.
HRSC will also support GTG’s market entry through the provision of services including;
Chinese company registration,
Free office space in the zone,
Marketing assistance – providing a link with government sectors, hospitals and enterprise,
Assist in process to obtain CFDA approval for GTG’s risk assessment tests; this will dramatically fastrack the process,
Obtain test samples to undertake new product development for the Chinese ethnic population.
The formal invitation follows on from a recent visit to Hainan by GTG’s CEO, Dr Paul Kasian and representatives from Beijing Zishan Health Consultancy Limited (“Zishan”), with whom GTG has signed a Heads of Agreement (as announced to the market on 14 August 2018).
Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The invitation is a significant first step to advance the adoption of genetic risk assessment tests in the region. We are grateful for the support we have received from HRSC and its commitment to continue to work with GTG to enable a successful outcome in China.”
Für alle,die noch dabei sind oder traden anbei der ausführliche Bericht:
© 1998-2018 / cash
| Impressum |